Due to the fact that CD8+ T cells are the most significant effector T cells in current tumor immunotherapy [41], CD8+ T cells detect tumor-associated antigens on the surface of cancer cells as major histocompatibility complex class I molecules [42]. The gene discussed is CD8A; the disease is cancer.